Effects of joint administration of imipramine and amantadine in patients with drug-resistant unipolar depression

Polish Journal of Pharmacology

Volumn 56, Issue 6, 2004, Pages 735-742

  Rogóz, Zofia ^a   Dziedzicka Wasylewska, Marta ^a   Daniel, Władysława A ^a   Wójcikowski, Jacek ^a   Dudek, Dominika ^b   Wróbel, Andrzej ^b   Zieba, Andrzej ^b  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Amantadine; Clinical and pharmacokinetic studies; Human; Imipramine; Therapy resistant unipolar depression

Indexed keywords

AMANTADINE; AMANTIX; AMITRIPTYLINE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; CYTOCHROME P450 1A2; CYTOCHROME P450 3A4; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENTIATION; DRUG WITHDRAWAL; FEMALE; HAMILTON SCALE; HUMAN; HYPOTENSION; MAJOR DEPRESSION; MALE; MONOTHERAPY; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; XEROSTOMIA;

ADULT; AMANTADINE; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMIPRAMINE; MALE; MIDDLE AGED;

EID: 14244264531     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Beck AT, Rush AJ, Shaw BF, Emery G: Cognitive Therapy of Depression. Gulford Press, New York, 1979.
2. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH: Antidepressant effects of ketamine in depressed patients. Biol Psychiatry, 2000, 47, 351-354.
3. Danysz W, Parsons CG, Kornhuber J, Schmidt WJ, Quack G: Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents - preclinical studies. Neurosci Biobehav Rev, 1997, 21, 455-468.
4. D'Aquila PS, Collu M, Gessa GL, Serra G: The role of dopamine in the mechanism of action of antidepressant drugs. Eur J Pharmacol, 2000, 405, 365-373.
5. 3 receptors in peripheral blood lymphocytes of the patients with drug-resistant unipolar depression. Pol J Pharmacol, 2002, 54, 703-706.
6. 2 receptor SPECT before and after antidepressant therapy. Psychopharmacology, 1996, 126, 91-94.
7. Frank E, Prien RF, Jarrett RB: Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Arch Gen Psychiatry, 1991, 48, 851-855.
8. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry, 1960, 23, 56-62.
9. Huber TJ, Dietrich DE, Emrich HM: Possible use of amantadine in depression. Pharmacopsychiatry, 1999, 32, 47-55.
10. 3 dopamine receptor mRNA in blood lymphocytes. Proc Natl Acad Sci USA, 2001, 98, 625-628.
11. Klimek V, Schenck JE, Han H, Stockmeier CA, Ordway G: Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study. Biol Psychiatry, 2002, 52, 740-748.
12. Korstein SG, Schneider RK: Clinical features of treatment-resistant depression. J Clin Psychiatry, 2001, 62, Suppl 10, 18-25.
13. Lambert G, Johansson M, Agren H, Friberg P: Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: evidence in support of the catecholamine hypothesis of mood disorders. Arch Gen Psychiatry, 2000, 57, 787-793.
14. 3 receptors in the rat brain. Eur J Pharmacol, 1998, 351, 31-37.
15. 3 dopamine receptor mRNA expression in lymphocytes from patients with Parkinson's disease. Neurology, 1996, 46, 791-795.
16. Nierenberg AA, Molroy R: Declaration of treatment failures. Mod Probl Pharmacopsychiatry, 1997, 25, 17-33.
17. Paul IA, Skolnick P: Glutamate and depression. Clinical and preclinical studies. Ann NY Acad Sci, 2003, 1003, 250-272.
18. Perugi G, Toni C, Ruffolo G, Frare F, Akiskal H: Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series. Pharmacopsychiatry, 2001, 34, 137-141.
19. Prien RF, Carpenter LL, Kupfer DJ: The definition and operational criteria for treatment outcome of major depressive disorder. Arch Gen Psychiatry, 1991, 48, 796-800.
20. 3H]7-OH--DPAT. J Neuroimmunol, 1995, 58, 139-144.
21. Riso LP, Thase ME, Howland RH: A prospective test of criteria for response, remission, relapse, recovery, and recurrence in depressed patients treated with cognitive behavioral therapy. J Affect Dissord, 1997, 43, 131-142.
22. 4 dopamine receptor messenger RNA expression in lymphocytes from patients with major depression. Prog Neuro-Psychopharmacol Biol Psychiatry, 2002, 26, 1155-1160.
23. 3 receptors in rats. J Physiol Pharmacol, 2003, 54, 257-270.
24. 3 receptors in the rat brain differentiated by agonist and antagonist binding - an autoradiographic analysis. Naunyn Schmiedeberg's Arch Pharmacol, 1999, 359, 179-186.
25. Rogóz Z, Skuza G, Kuśmider M, Wójcikowski J, Kot M, Daniel WA: Synergistic effect of imipramine and amantadine in the forced swimming test in rats. Behavioral and pharmacokinetics studies. Pol J Pharmacol, 2004, 56, 179-185.
26. Rogóz Z, Skuza G, Maj J, Danysz W: Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats. Neuropharmacology, 2002, 42, 1024-1030.
27. Sourey D, Amsterdam J, de Montigny C, Lecrubier Y, Mongomery S, Lipp O, Racagni G et al.: Treatment-resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol, 1999, 185, 1-10.
28. Stryjer R, Strous RD, Shaked G, Bar F, Feldman B, Kotler M, Polak L et al.: Amantadine as augmentation therapy in the management of treatment-resistant depression. Int Clin Psychopharmacol, 2003, 18, 93-96.
29. Suftin TA, Jusko W: High-performance liquid chromatographic assay for imipramine, desipramine, and their 2-hydroxylated metabolites. J Pharmacol Sci, 1979, 68, 703-705.
30. Takahashi T, Yamashita H, Zhang Y-X, Nakamura S: Inhibitory effect of MK-801 on amantadine-induced dopamine release in the rat striatum. Brain Res Bull, 1996, 41, 363-367.